BioXcel Therapeutics Announces Reverse Stock Split
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will effect a 1-for-16 reverse stock split of its common stock.
(RTTNews) - BioXcel Therapeutics, Inc. (BTAI), Thursday announced a reverse stock split of 1-for-16 to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq ...
Most Wall Street analysts expect shares of Nvidia and Lam Research to soar in 2025. Nvidia's leadership in artificial ...
Holdings announced the date of effectiveness and the ratio of a forthcoming reverse stock split of the Company’s Common Stock. On January 13, 2025, the Company announced, on a Current Report on Form 8 ...
Shareholders of Al-Jouf Mineral Water Bottling Co. will discuss reducing the stock’s nominal value from SAR 10 to SAR 0.5 ...
Netflix ( NFLX 0.22%) has shown investors once again who's on top of the streaming industry. On Jan. 21, the company reported ...
Honeywell said it will split into three companies. The aerospace giant said it will separate its aerospace, automation and ...
Tonix Pharmaceuticals (TNXP) stock plunged after the company carried out a 1-for-100 reverse stock split as it awaits approval for its ...
Info Edge shares currently carry a face value of ₹10 each and this will be the first instance of the company dividing its stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback